CD8A and neoplasm: However, given its recently described role as suppressor of effector CD8 T-cells,29 CEACAM6 is currently considered an immune checkpoint molecule and as such could be targeted by drugs designed to block its activity in cancer patients.28 Additionally, in preclinical mouse models antibodies targeting CEACAM6 have been shown to inhibit tumor growth and metastasis.26,59